UNSPSC 51292910: Maroxepin

This classification denotes an antidepressant agent with the molecular formula C19H19NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XG4094G0OY, chemically known as 2,3,4,5-tetrahydro-3-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-d)azepine but generally known as maroxepin, which bears US NIH Compound Identifier 68858. European Medicines Agency schedules Maroxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08651MIG.

UNSPSC 51292910 Maroxepin (Commodity) does not align with recent state and local procurement activity tagged under this code. The three most recent solicitations involve naloxone and drug-deactivation systems, a direct-to-manufacturer pharmacy initiative, and generic multi-source pharmaceuticals and over-the-counter products — none of which are maroxepin or related to the code's nominal scope. Maroxepin is a pharmaceutical compound with a narrowly defined therapeutic application, yet the tagged opportunities span opioid-reversal agents, pharmacy benefit program redesign, and wholesale generic-drug distribution channels. This mismatch suggests either miscoding at the source or minimal genuine state and local procurement activity under this Commodity code in recent months.

The geographic distribution of the three opportunities spans Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP, a multistate cooperative purchasing vehicle serving Minnesota and Oregon participants), with response deadlines between April 2026 and July 2026. Seminole County issued an IFB for 1,900 units of naloxone and 800 safe drug-deactivation systems annually with a July 26, 2023 deadline; Texas HHS posted an RFI on April 3, 2026 to assess direct-to-manufacturer prescription capabilities; and MMCAP issued an RFP due March 26, 2026 for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. Without confirmed recent opportunities that genuinely fit the maroxepin category, this code warrants monitoring for corrected or reclassified solicitations rather than active pursuit.